305 related articles for article (PubMed ID: 31597698)
21. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model.
Armengol C; Cairo S; Fabre M; Buendia MA
Int J Biochem Cell Biol; 2011 Feb; 43(2):265-70. PubMed ID: 19646548
[TBL] [Abstract][Full Text] [Related]
22. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
23. Babao Dan is a robust anti-tumor agent via inhibiting wnt/β-catenin activation and cancer cell stemness.
Xie X; Chen J; Wo D; Ma E; Ning Y; Peng J; Zhu W; Ren DN
J Ethnopharmacol; 2021 Nov; 280():114449. PubMed ID: 34332067
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
25. CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X; Kiss A; Schaff Z; Evert K; Zhang Y; Zhong S; Wang J; Evert M; Calvisi DF; Chen X
Pediatr Blood Cancer; 2020 May; 67(5):e28221. PubMed ID: 32124532
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
Schmidt A; Braeuning A; Ruck P; Seitz G; Armeanu-Ebinger S; Fuchs J; Warmann SW; Schwarz M
Toxicology; 2011 Mar; 281(1-3):7-14. PubMed ID: 21237236
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
Jeng YM; Wu MZ; Mao TL; Chang MH; Hsu HC
Cancer Lett; 2000 Apr; 152(1):45-51. PubMed ID: 10754205
[TBL] [Abstract][Full Text] [Related]
28. A novel tissue-based ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors.
Dubbink HJ; Hollink IHIM; Avenca Valente C; Wang W; Liu P; Doukas M; van Noesel MM; Dinjens WNM; Wagner A; Smits R
Pediatr Blood Cancer; 2018 Jun; 65(6):e26991. PubMed ID: 29446530
[TBL] [Abstract][Full Text] [Related]
29. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
30. ACLY-β-catenin axis modulates hepatoblastoma cell proliferation.
Lin Y; Fang H; Ma C; Zhou J; Ding M; Sun H; Xu Y; Shan Y; Gao H; Yang L; Gu S; Li H
Biochem Biophys Res Commun; 2023 Jun; 663():104-112. PubMed ID: 37121120
[TBL] [Abstract][Full Text] [Related]
31. SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway.
Ge J; Zheng Q; Qu H; Zhao Z; Xu Y; Wang H; Gao H; Zhan J
J Cancer Res Ther; 2022 Apr; 18(2):370-377. PubMed ID: 35645102
[TBL] [Abstract][Full Text] [Related]
32. KDM1A drives hepatoblastoma progression by activating the Wnt/β-catenin pathway through inhibition of DKK3 transcription.
Ji C; Chen L; Yuan M; Xie W; Sheng X; Yin Q
Tissue Cell; 2023 Apr; 81():101989. PubMed ID: 36642006
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
34. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma.
Bläker H; Hofmann WJ; Rieker RJ; Penzel R; Graf M; Otto HF
Genes Chromosomes Cancer; 1999 Aug; 25(4):399-402. PubMed ID: 10398436
[TBL] [Abstract][Full Text] [Related]
35. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
36. High frequency of beta-catenin mutations in hepatoblastoma.
Udatsu Y; Kusafuka T; Kuroda S; Miao J; Okada A
Pediatr Surg Int; 2001 Sep; 17(7):508-12. PubMed ID: 11666046
[TBL] [Abstract][Full Text] [Related]
37. Hepatoblastoma--an attempt of histological subtyping on fine-needle aspiration material.
Barwad A; Gupta N; Gupta K; Rajwanshi A; Marwaha RK; Rao KL; Dey P; Srinivasan R; Nijhawan R
Diagn Cytopathol; 2013 Feb; 41(2):95-101. PubMed ID: 22362636
[TBL] [Abstract][Full Text] [Related]
38. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
39. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
